参考文献/References:
[1] SIMO R,HERNANDEZ C.Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence[J].Prog Retin Eye Res,2015,48(9):160-180.
[2] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,30(10):893-942.
CHINESE DIABETES SOCIETY.China guideline for type 2 diabetes mellitus (2013 Edition) [J].Chin J Endocrinol Metab,2014,30(10):893-942.
[3] 王月欣,陈松.糖尿病视网膜病变神经损伤的发病机制和保护防治研究进展[J].中华眼底病杂志,2014,30(2):209-211.
WANG YX,CHEN S.Research advance of nerve lesions in the pathogenesis of diabetic retinopathy and treatment of nerve protection[J].Chin J Ocul Fundus Dis,2014,30(2):209-211.
[4] HERNANDEZ C,DLMONTE M,SIMO R,CASINI G.Neuroprotection as a therapeutic target for diabetic retinopathy[J].J Diabetes Res,2016,2016 (24):9508541.
[5] SIMO R,HERNANDEZ C.Neurodegeneration is an early event in diabetic retinopathy:therapeutic implications[J].Br J Ophthalmol,2012,96(10):1285-1290.
[6] HERNANDEZ C,GARCIA-RAMIREZ M,CORRALIZA L,FERNADEZ-CARNEADO J,FARRERA-SINFREU J,PONSATI B,et al.Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes[J].Diabetes,2013,62(7):2569-2578.
[7] 刘姝林,陈有信.SIRT1在糖尿病视网膜病变发病机制中的作用[J].国际眼科纵览,2013,37(6):374-378.
LIU SL,CHEN YX.The role of SIRT1 in the pathogenesis of diabetic retinopathy[J].Int Rev Ophthalmol,2013,37(6):374-378.
[8] 彭惠,洪苏玲,李平华.p38丝裂原活化蛋白激酶信号通路在糖尿病性视网膜病变中的作用研究进展[J].眼视光学杂志,2007,9(2):139-141.
PENG H,HONG SL,LI PH.Recent progress in research on the p38 MAPK cell signal pathway in diabetic retinopathy[J].Chin J Opt Ophthalmol,2007,9(2):139-141.
[9] 李东洁,吴迪,张旭乡.糖尿病视网膜神经节细胞损伤的研究进展[J].国际眼科杂志,2016,16(4):670-672.
LI DJ,WU D,ZHANG XX.Research advance of diabetic retinal ganglion cell lesions[J].Int Eye Sci,2016,16(4):670-672.
[10] 于常红,韩彦弢,曹玉,安明,时肖,杨军廷,等.左卡尼汀对糖尿病大鼠视网膜神经节细胞保护作用的实验研究[J].中国药理学通报,2013,29(11):1502-1505.
YU CH,HAN YT,CAO Y,AN M,SHI X,YANG JT,et al.Protective effect of L carnitine on retinal ganglion cells in the diabetic rat[J].Chin Pharmacol Bulletin,2013,(11):1502-1505.
[11] KIM D,NGUYEN MD,DOBBIN MM,FISCHER A,SANANBENESI F,RODGERS JT,et al.SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis[J].EMBO J,2007,26(13):3169-3179.
[12] 诸葛淳淳,徐国彤,徐晶莹.去乙酰化酶Sirt1在视神经视网膜疾病中的神经保护作用[J].国际眼科纵览,2012,36(4):222-227.
ZHU-GE CC,XU GT,XU JY.The neuroprotective role of Sirt1 in retinal and optic nerve diseases [J].Int Rev Ophthalmol,2012,36(4):222-227.
[13] BORRA MT,SMITH BC,DENU JM.Mechanism of human SIRT1 activation by resveratrol[J].J Biol Chem,2005,280(17):17187-17195.
[14] CAO D,WANG M,QIU X,LIU D,JIANG H,YANG N,et al.Structural basis for allosteric,substrate-dependent stimulation of SIRT1 activity by resveratrol[J].Genes Dev,2015,29(12):1316-1325.
[15] LI YH,ZHUO YH,LU L,CHEN LY,HUANG XH,ZHANG JL,et al.Caspase-dependent retinal ganglion cell apoptosis in the rat model of acute diabetes[J].Chin Med J (Engl),2008,121(24):2566-2571.
[16] ADAMIEC-MROCZEK J,ZZJAC-PYTRUS H,MISIUK-HOJLO M.Caspase-dependent apoptosis of retinal ganglion cells during the development of diabetic retinopathy[J].Adv Clin Exp Med,2015,24(3):531-535.
[17] 苟文军,吕红彬,杨旭,李恒,刘灵琳,李利文,等.罗格列酮对糖尿病大鼠视网膜神经节细胞凋亡的影响[J].眼科新进展,2016,36(9):818-821.
GOU WJ,LV HB,YANG X,LI H,LIU LL,LI LW,et al.Effects of rosiglitazone on retinal ganglion cells apoptosis in rats with diabetes mellitus[J].Rec Adv Ophthalmol,2016,36(9):818-821.
[18] 李德冠,樊飞跃,孟爱民.p38 MAPK通路在造血系统调节中的作用[J].中国药理学通报,2011,27(1):4-6.
LI DG,FAN FY,MENG AM.p38 MAPK signaling pathways in the regulation of hematopoietic system[J].Chin Pharmacol Bull,2011,27(1):4-6.
[19] 章必成,张巍.TNF,p38 MAPK与细胞凋亡[J].国外医学(生理、病理科学与临床分册),2001,21 (6):464-466.
ZHANG BC,ZHANG W.p38 MAPK and cell apoptosis[J].Foreign Med Sci(Sec Pathophysiol Clin Med),2001,21(6):464-466.
[20] 李永浩,吕林,陈凌燕,黄新华,张静琳,李石毅,等.P38丝裂素活化蛋白激酶信号通路阻断对糖尿病鼠早期血视网膜屏障和视网膜节细胞的保护作用[J].中华眼底病杂志,2010,26(2):139-142.
LI TH,LV L,CHEN LY,HUANG XH,ZHANG JL,LI SY,et al.Protective effect of blocking the signal path of p38 mitogen activated protein kinase on blood retinal barrier and retinal ganglion cells in early diabetic rats[J].Chin J Ocul Fundus Dis,2010,26(2):139-142.
[21] KUME S,KITADA M,KANASAKI K,MAEGAWA H,KOYA D.Anti-aging molecule,Sirt1:a novel therapeutic target for diabetic nephropathy[J].Arch Pharm Res,2013,36(2):230-236.
相似文献/References:
[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[6]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[7]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[8]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[9]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[10]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.